pros and cons of glp-1 Do The Benefits Drugs OutWeigh the Negatives? The Impact of Glucagon-like Peptide-1

Obesity is the entry point, but cardiovascular disease, kidney disease, MASH, sleep apnea, and metabolic syndrome may define the long-term value

La diversin debe ser el centro y no un medio para cubrir gastos

Back to Journals Drug Design, Development and Therapy Volume 13 The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date Authors Antza C , Nirantharakumar K , Doundoulakis I, Tahrani AA, Toulis KA Received 31 October 2018 Accepted for publication 27 June 2019 Published 22 August 2019 Volume 2019:13 Pages 29852996 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 3 Editor who approved publication: Dr Tuo Deng Christina Antza, 1,* Krishnarajah Nirantharakumar, 2,* Ioannis Doundoulakis, 3 Abd A Tahrani, 46 Konstantinos A Toulis 2, 3 1 3rd Department of Internal Medicine, Papageorgiou Hospital, Aristotle University, Thessaloniki, Greece

doi: 10.1111/dom.14725 45 CrinAGrugniG